SCHEMBL17295

SCHEMBL17295

CCOC(=O)[C@H](Cc1cccc(OC)n1)NC(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRB P23467 1/20 0.39
KLK5 Q9Y337 1/20 0.39
SCN9A Q15858 1/20 0.38
TGFBR1 P36897 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
TP53 P04637 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
TACR1 P25103 2/20 0.35
AURKB Q96GD4 2/20 0.35
EGFR P00533 1/20 0.35
RAF1 P04049 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17294 1.00 PTPRB (0.39) PTPRBKLK5SCN9ATGFBR1ALDH1A1
SCHEMBL18092 0.89 ACE (0.45) PTPRBKLK5TGFBR1ACECTSB
SCHEMBL18091 0.89 ACE (0.45) PTPRBKLK5TGFBR1ACECTSB
SCHEMBL30916055 0.82 KLK5 (0.47) KLK5TACR1ACECTSBCTSS
SCHEMBL16909 0.81 TP53 (0.41) ALDH1A1MAPTTP53PSMB5
SCHEMBL16908 0.81 TP53 (0.41) ALDH1A1MAPTTP53PSMB5
SCHEMBL17583 0.80 KLK5 (0.41) PTPRBKLK5SCN9AALDH1A1MAPT
SCHEMBL17582 0.80 KLK5 (0.41) PTPRBKLK5SCN9AALDH1A1MAPT
SCHEMBL17177 0.80 CACNA1B (0.49) KLK5SCN9ATP53GFERHSD17B10
SCHEMBL17178 0.80 CACNA1B (0.49) KLK5SCN9ATP53GFERHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 PTPRB 1451/4885KLK5 376/4885SCN9A 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.